TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22101228

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention using Motivational Interviewing techniques
Number of subjects: 632

Group type: COMPARATOR
Intervention: Minimal mail-out intervention
Number of subjects: 632
Study: 20030435

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 single-injection formulation
Number of subjects: 253
Study: 18930254

Group type: EXPERIMENTAL
Intervention: Low fat vegan diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Soy beverage
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lycopene supplement
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation
Number of subjects: 9
Study: 15879163

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 10
Study: 14654762

Group type: EXPERIMENTAL
Intervention: Diuretic-based regimen (usually bendroflumethiazide)
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor regimen (usually lisinopril)
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Active treatment (combined diuretic and ACE inhibitor)
Number of subjects: 1283
Study: 11127968

Group type: EXPERIMENTAL
Intervention: Vitamin A; specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies and randomized controlled trials
Number of subjects: 0
Study: 8085494

Group type: EXPERIMENTAL
Intervention: Questionnaire on sexuality aspects
Number of subjects: 240
Study: 2511939

Group type: EXPERIMENTAL
Intervention: Advice on early mobilisation
Number of subjects: 247

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 247

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Advice or physiotherapy
Number of subjects: 247
Study: 836153

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen freezing method
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cryokwik freezing method
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both methods of freezing (Liquid nitrogen and Cryokwik)
Number of subjects: 16
Study: 31353172

Group type: EXPERIMENTAL
Intervention: Skeletal advancement surgery with sagittal split ramus osteotomy (SSRO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Skeletal advancement surgery with mandibular distraction osteogenesis (MDO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 18
Study: 31216388

Group type: EXPERIMENTAL
Intervention: Pressure injury observed within the first 36 hours of hospital admission
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Age, multiple comorbidities, and living in an aged care facility
Number of subjects: 1047
Study: 28736413

Group type: EXPERIMENTAL
Intervention: Parent mentor (PM) intervention built on community partnerships
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Parent mentor (PM) intervention
Number of subjects: 329
Study: 24368725

Group type: EXPERIMENTAL
Intervention: 3‐day intravenous infusion of creatine phosphate (CP) after PCI
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 400
Study: 23734858

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 weeks
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) for 16 weeks
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both CBT and CM for 16 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: No additional behavioral treatment (NT) for 16 weeks
Number of subjects: 202
Study: 20700742

Group type: EXPERIMENTAL
Intervention: Absorbable cervical tourniquet (group 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No absorbable cervical tourniquet (group 2)
Number of subjects: 44
Study: 17885079

Group type: EXPERIMENTAL
Intervention: Histopathology assessment by 3 experienced hematopathologists for 16 different morphologic features and overall diagnosis according to WHO classification.
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Reticulin grade assessment.
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Factor analysis of histopathological features.
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Comparison of clinical and laboratory features at presentation, JAK2 status, survival, thrombosis, major hemorrhage, or myelofibrotic transformation between patients labeled as 'prefibrotic myelofibrosis' or 'true ET'.
Number of subjects: 370
Study: 16584506

Group type: EXPERIMENTAL
Intervention: Cabergoline therapy (0.5-1 mg twice per week) for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 15
Study: 14597512

Group type: EXPERIMENTAL
Intervention: 6 hours of patching per day
Number of subjects: 175

Group type: COMPARATOR
Intervention: Full-time patching (all hours or all but 1 hour per day)
Number of subjects: 175
Study: 11038977

Group type: EXPERIMENTAL
Intervention: Drugs for nourishing the kidney‐yin, invigorating blood circulation and removing blood stasis
Number of subjects: 35

Group type: COMPARATOR
Intervention: Euglucon and other routine drugs
Number of subjects: 35
Study: 8769908

Group type: EXPERIMENTAL
Intervention: Advance directive videotape
Number of subjects: 36

Group type: COMPARATOR
Intervention: Health-relative videotape
Number of subjects: 36
Study: 8383548

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 3948126

Group type: EXPERIMENTAL
Intervention: Rubidazone 450 mg/m2
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rubidazone 300 mg/m2
Number of subjects: 34
Study: 29728551

Group type: EXPERIMENTAL
Intervention: Hawley retainer (HR)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer (VFR) with thickness of 1.5 mm
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer (VFR) with thickness of 1 mm
Number of subjects: 66
Study: 27523625

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail without distal locking screw (Unlocking Group - UG)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Proximal femoral nail with distal locking screw (Locking Group - LG)
Number of subjects: 333
Study: 24531549

Group type: EXPERIMENTAL
Intervention: Buspirone (serotonin receptor type 1A agonist) prior to levodopa administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa (identical doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study: 22133521

Group type: EXPERIMENTAL
Intervention: High-quality foster care (FCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (CAUG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No plasticity alleles
Number of subjects: 0
Study: 20541178

Group type: EXPERIMENTAL
Intervention: Cluster II (higher neuroticism, lower control over CB symptoms)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cluster II (higher rates of comorbid anxiety disorders and cluster B personality disorders)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 68
Study: 18702965

Group type: EXPERIMENTAL
Intervention: Statin therapy (rosuvastatin 10 or 20 mg, atorvastatin 10 or 20 mg, simvastatin 20 or 40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 0
Study: 15936647

Group type: EXPERIMENTAL
Intervention: Black currant seed oil (3 g/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fish oil (2.8 g/day)
Number of subjects: 15
Study: 14616666

Group type: EXPERIMENTAL
Intervention: Coblation tonsillotomy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Coblation tonsillectomy
Number of subjects: 14
Study: 11228758

Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Metformin (M) and Glibenclamide (G)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: High proinsulin levels
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Meal-stimulated glucose (net AUC)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Proinsulin change after therapy
Number of subjects: 165
Study: 8759264

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% drops
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sublingual timolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline drops (placebo)
Number of subjects: 12
Study: 1930769

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure at 0.05 ppm with peaks of 2.0 ppm for 15 minutes; bronchoalveolar lavage 3.5 hours after exposure
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Continuous nitrogen dioxide exposure at 0.60 ppm; bronchoalveolar lavage 18 hours later
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Continuous nitrogen dioxide exposure at 1.5 ppm; bronchoalveolar lavage 3.5 hours after exposure
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Carbachol exposure (10 mg/mL) after nitrogen dioxide exposure
Number of subjects: 38

Group type: COMPARATOR
Intervention: Carbachol exposure (10 mg/mL) after air exposure
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage analysis during all three phases
Number of subjects: 38
Study: 6627695

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 30 mg daily
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30113395

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) 6 µg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Phenylephrine (PE) 100 µg
Number of subjects: 112
Study: 29764293

Group type: EXPERIMENTAL
Intervention: Biological educational intervention
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Psychosocial educational intervention
Number of subjects: 327

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 327
Study: 27342831

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 436
Study: 24666617

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (dAPT) - clopidogrel (75 mg) plus aspirin (300 mg)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Aspirin-monotherapy (300 mg)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (dAPT)
Number of subjects: 219
Study: 20497186

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no etidronate)
Number of subjects: 87
Study: 19328650

Group type: EXPERIMENTAL
Intervention: Acupressure bands with neutral information (Arm 2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Acupressure bands with positive information (Arm 3)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care (Arm 1)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combined acupressure bands (Arms 2 and 3)
Number of subjects: 88
Study: 17379678

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 24

Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 24
Study: 15673224

Group type: EXPERIMENTAL
Intervention: Infant simulator with New York State parenting curriculum
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 236
Study: 11230779

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: glibenclamide
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 9699192

Group type: EXPERIMENTAL
Intervention: Preparation intervention (health education sessions)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Preparation intervention
Number of subjects: 86
Study: 7908610

Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg/d (high dose)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Bucindolol 12.5 mg/d (low dose)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Bucindolol 50 mg/d (medium dose)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 3171039

Group type: EXPERIMENTAL
Intervention: Treatment for isolated systolic hypertension
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 28473401

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 26253332

Group type: EXPERIMENTAL
Intervention: Prevention of Delirium Programme
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 24409029

Group type: EXPERIMENTAL
Intervention: Cognitive activity combined with physical exercise (CAE), n=11
Number of subjects: 30

Group type: COMPARATOR
Intervention: Only cognitive activity (CA), n=9
Number of subjects: 30
Study: 21907780

Group type: EXPERIMENTAL
Intervention: ModraDoc001 15 mg capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: docetaxel premix solution (TAXOTERE)
Number of subjects: 0
Study: 19595438

Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Number of subjects: 143

Group type: COMPARATOR
Intervention: Trientine
Number of subjects: 143
Study: 17032704

Group type: EXPERIMENTAL
Intervention: Intervention with parental involvement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intervention alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 12642306

Group type: EXPERIMENTAL
Intervention: Single lyophilisate (204 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Three conventional eye drops (40 ml fluorescein SE Thilo 0.17%)
Number of subjects: 22
Study: 10673700

Group type: EXPERIMENTAL
Intervention: 2 mg/kg LSF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mg/kg LSF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9266139

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies to block TNF-alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: IL-1 receptor antagonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies with monoclonal antibodies and long-acting rheumatic drugs (e.g., methotrexate)
Number of subjects: 0
Study: 8184764

Group type: EXPERIMENTAL
Intervention: Biplane left ventriculography at 3 weeks and 1 year after myocardial infarction
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients selected for late ventricular enlargement (change in ED volume > 20 ml, n = 19)
Number of subjects: 52
Study: 3513801

Group type: EXPERIMENTAL
Intervention: Indomethacin, 25 mg, four times a day during therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo, four times a day during therapy
Number of subjects: 19
Study: 30088841

Group type: EXPERIMENTAL
Intervention: Probiotic preparation containing Lactobacillus, Bifidobacterium, and Streptococcus spp., 2 capsules daily for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo, daily for 14 days
Number of subjects: 100
Study: 29342390

Group type: EXPERIMENTAL
Intervention: Household-contact investigation plus standard passive case finding
Number of subjects: 25707

Group type: COMPARATOR
Intervention: Passive case finding alone
Number of subjects: 25707
Study: 25802980

Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid) 1060 mg day(‐1)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid) 900 mg day(‐1)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid)
Number of subjects: 155
Study: 24670088

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg)
Number of subjects: 12
Study: 22738908

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control condition (for PTSD patients)
Number of subjects: 69
Study: 19404656

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 140
Study: 17137468

Group type: EXPERIMENTAL
Intervention: Early Treatment
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 165
Study: 15147016

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) system using characteristic-point-based fuzzy inference system (CPFIS)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (normal images)
Number of subjects: 109
Study: 12070645

Group type: EXPERIMENTAL
Intervention: ACD anticoagulant (group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No additives (group B)
Number of subjects: 81
Study: 9805326

Group type: EXPERIMENTAL
Intervention: Early Alzheimer's disease (AD) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early vascular dementia (VaD) patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall naming errors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic errors
Number of subjects: 0
Study: 7705801

Group type: COMPARATOR
Intervention: L‐alanyl‐L‐tyrosine (Ala‐Tyr)
Number of subjects: 13

Group type: COMPARATOR
Intervention: glycyl‐L‐tyrosine (Gly‐Tyr)
Number of subjects: 13

Group type: COMPARATOR
Intervention: N‐acetyl‐L‐tyrosine (Nac‐Tyr)
Number of subjects: 13
Study: 2198140

Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 356598

Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30328153

Group type: EXPERIMENTAL
Intervention: High-vitamin level diet (DSM vitamin regimen)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Medium-vitamin level diet (50% low-vitamin level diet and 50% high-vitamin level diet)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Low-vitamin level diet (70% NRC vitamin regimen)
Number of subjects: 432
Study: 28478214

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide gel in tray
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide strip
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison between tray and strip groups
Number of subjects: 26
Study: 25196742

Group type: EXPERIMENTAL
Intervention: Disposable bed bath
Number of subjects: 58

Group type: COMPARATOR
Intervention: Traditional basin bed bath
Number of subjects: 58
Study: 23351409

Group type: EXPERIMENTAL
Intervention: 500 mL low-calorie cranberry juice cocktail (CJC) per day for 4 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: 500 mL placebo juice (PJ) per day for 4 weeks
Number of subjects: 35
Study: 22093840

Group type: EXPERIMENTAL
Intervention: eFATE
Number of subjects: 83

Group type: COMPARATOR
Intervention: Routine methods
Number of subjects: 83
Study: 19672253

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ustekinumab (infliximab-experienced subgroup)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (infliximab-experienced subgroup)
Number of subjects: 104
Study: 17453399

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Indomethacin (100 mg daily)
Number of subjects: 100
Study: 15794388

Group type: EXPERIMENTAL
Intervention: LA 600 mg twice a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LA 1200 mg once a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LA 1200 mg twice a day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LA (all doses)
Number of subjects: 37
Study: 12207826

Group type: EXPERIMENTAL
Intervention: Use of diagnostic and therapeutic algorithms in 11 nursing homes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual practice in 11 nursing homes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Use of diagnostic and therapeutic algorithms
Number of subjects: 22
Study: 10713866

Group type: EXPERIMENTAL
Intervention: Topical application of Lem1 (natural compound from lemon oil)
Number of subjects: 0
Study: 8547043

Group type: EXPERIMENTAL
Intervention: Laser treatment (pulsed tunable dye laser)
Number of subjects: 8
Study: 1919822

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30
Study: 6255982

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of ACTH
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 20
Study: 31994186

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 6986

Group type: EXPERIMENTAL
Intervention: Simulated adolescent data
Number of subjects: 6986
Study: 31575006

Group type: EXPERIMENTAL
Intervention: Cryotherapy applied in the pre‐ and postoperative periods (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cryotherapy applied only in the postoperative period (Group 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cold pack (gel ice) applied postoperatively (Group 3)
Number of subjects: 90
Study: 29232436

Group type: EXPERIMENTAL
Intervention: SOC plus a bioengineered ECM with living fibroblasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SOC plus a bioengineered ECM devoid of cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 25982014

Group type: EXPERIMENTAL
Intervention: MRI group (n = 175)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 275
Study: 23732957

Group type: EXPERIMENTAL
Intervention: Small group sexual and substance use risk reduction intervention based on empowerment theory
Number of subjects: 515

Group type: COMPARATOR
Intervention: Enhanced efficacious control condition
Number of subjects: 515
Study: 21241793

Group type: EXPERIMENTAL
Intervention: Higher Conscientiousness
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Higher Openness
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Goal striving (subcomponent of Conscientiousness)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Aesthetic interests (subcomponent of Openness)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Common health behaviors and chronic illness
Number of subjects: 200
Study: 19179549

Group type: COMPARATOR
Intervention: LV5FU2 alone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: LV5FU2 + IRI (irinotecan)
Number of subjects: 400